Sermorelin research

The Sermorelin evidence base cited here is 7 sources — 3 clinical, 2 review, 1 regulatory. Its strongest evidence is human — 3 clinical studies, most recently 1997 ("Endocrine and Metabolic Effects of Long-Term Administration of GHRH(1-29…"). Regulatory status: Previously FDA-approved.

Sermorelin and CJC-1295 are the two most-discussed GHRH analogs, so a direct comparison is useful. Both hit the GHRH receptor; the difference is half-life and the resulting GH-release pattern.

The short half-life that looks like a weakness is arguably the point: sermorelin's brief pulse mimics the body's own secretory rhythm and keeps somatostatin feedback intact, whereas DAC-CJC-1295's days-long elevation departs from that natural pulsatility. For the synergistic GH boost, GHRH analogs are usually paired with a GHRP (ghrelin-receptor agonist), not with each other — see Stacking.

• Sermorelin (GRF 1-29 / GHRH 1-29) is a synthetic 29-amino-acid peptide identical to the biologically active N-terminal fragment of human growth hormone-releasing hormone (GHRH), used to stimulate the body's own GH production.
• It works upstream of the pituitary — activating the same GHRHR that endogenous GHRH does — so GH release stays pulsatile and subject to somatostatin feedback, preserving the hypothalamic-pituitary axis rather than overriding it (the key contrast with exogenous GH).
• It was genuinely FDA-approved (Geref) for pediatric GH deficiency and diagnostic use, then voluntarily withdrawn in 2008 for commercial reasons — the FDA confirmed in 2013 it was NOT withdrawn for safety/efficacy, which is what makes it legally compoundable today under Section 503A.

Sermorelin is a synthetic peptide made of the first 29 amino acids of human GHRH — the shortest fully active fragment of the native hormone. Rather than supplying growth hormone directly, it prompts the pituitary to release the body's own GH, working through the same receptor and the same feedback controls as natural GHRH.

It is unusual among anti-aging peptides in having a real regulatory pedigree: it was FDA-approved as Geref for pediatric GH deficiency and as a diagnostic agent before being withdrawn in 2008 for purely commercial reasons. That history, plus a 2013 FDA confirmation that the withdrawal was not safety-related, is why licensed compounding pharmacies can legally prepare it by prescription today.

Sermorelin (also GRF 1-29 or GHRH 1-29) is the biologically active N-terminal fragment of the 44-amino-acid human GHRH molecule. Early-1980s research established that residues 1–29 retain full activity at the pituitary GHRH receptor, making sermorelin the shortest fully functional GHRH fragment. Its molecular weight is ≈ 3,358 Da.

What sets sermorelin apart from other GHRH analogs is its close structural identity to native GHRH. Unlike CJC-1295 — which adds amino-acid substitutions and (in its DAC form) an albumin-binding moiety to extend half-life to days — sermorelin's half-life is only ~11–12 minutes, producing brief, physiological GH pulses. Compared with tesamorelin (a 44-aa modified GHRH analog FDA-approved for HIV-associated lipodystrophy), sermorelin is smaller and less protease-resistant but has a longer clinical track record across more indications.

Responses vary with age, baseline GH/IGF-1, body composition, diet, and exercise. The following reflects patterns from clinical studies and prescriber experience.

Maximum benefit is generally seen at the 3–6-month mark with consistent use; providers typically reassess IGF-1 and clinical response at ~3-month intervals.

Sermorelin has a well-established safety profile from its years as an FDA-approved medication. The following come from clinical trials and post-marketing experience.

Precautions/contraindications: active malignancy (GH/IGF-1 may promote tumor growth); untreated hypothyroidism (impairs GH response — correct first); concomitant glucocorticoids (attenuate effect); obesity (blunted GH response). As a hormone-modulating therapy, use belongs under provider supervision with biomarker monitoring.

Sermorelin's regulatory history is unique among anti-aging peptides: it was once a fully FDA-approved medication with a completed NDA, clinical-trial data, and an established safety profile.

• 1988: FDA orphan-drug designation for idiopathic/organic GH deficiency in children.
• Sep 1997: NDA 20-443 approved (Geref, pediatric GHD treatment).
• Dec 2008: EMD Serono notifies FDA of voluntary discontinuation (commercial reasons).
• Jun 2009: FDA formally withdraws NDA approval.
• Mar 2013: FDA Federal Register determination confirms Geref was NOT withdrawn for reasons of safety or effectiveness.

The 2013 determination is what enables legal compounding: under Section 503A, licensed pharmacies may prepare sermorelin per-prescription for individual patients, and 503B outsourcing facilities may compound it under FDA oversight (pharmaceutical-grade API with a valid COA). Sermorelin is not a controlled substance, but it is a prescription medication — it cannot be sold OTC, as a supplement, or marketed for human use without a valid prescription.

Sermorelin is explicitly prohibited by WADA under Section S2.2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics) — specifically S2.2.4 as a GHRH analog, alongside CJC-1295 and tesamorelin. The ban applies at all times, in- and out-of-competition. All GH secretagogues — GHS-R agonists (ipamorelin, ibutamoren) and GHRH analogs (sermorelin, CJC-1295, tesamorelin) — are banned for their capacity to raise GH and IGF-1. A Therapeutic Use Exemption is theoretically possible but very difficult for S2 substances; tested athletes should treat sermorelin as a disqualifying violation.

All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.